Genprex Q1 net loss widens 13% to $4.46 million year over year

Genprex

Genprex

GNPX

0.00
  • Genprex posted a net loss of USD 4.46 million for the quarter ended March 31, 2026, widening 13% from the year-earlier period.
  • Research and development expense rose 8% to USD 2.75 million, while general and administrative costs climbed 22% to USD 1.75 million.
  • Other income increased to USD 31,748, while cash and cash equivalents totaled USD 18.05 million as of March 31, 2026.
  • During the quarter, 5,714,798 shares were sold under the 2023 at-the-market facility for net proceeds of about USD 13.36 million.
  • Operationally, Genprex continued enrolling Acclaim-1 and Acclaim-3, targeting interim enrollments in the first half of 2026 with interim analyses expected in the second half of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-016755), on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.